ESMO Open

Additional Metrics

Top Publications

• Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.

  Laurence Albiges;Nizar M. Tannir;Mauricio Burotto;David McDermott;David McDermott

  (2020)
  458 Citations

• Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers

  (2021)
  340 Citations

• Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

  (2022)
  296 Citations

• Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies

  (2022)
  275 Citations

• Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment

  (2022)
  257 Citations

• Adolescents and young adults (AYA) with cancer: a position paper from the AYA Working Group of the European Society for Medical Oncology (ESMO) and the European Society for Paediatric Oncology (SIOPE)

  A. Ferrari;D. Stark;F.A. Peccatori;L. Fern

  (2021)
  244 Citations

• Anxiety and depression in adult cancer patients: ESMO Clinical Practice Guideline

  (2023)
  214 Citations

• First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.

  M. Reck;T.-E. Ciuleanu;M. Cobo;M. Schenker

  (2021)
  185 Citations

• Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations

  M. Riudavets;I. Sullivan;P. Abdayem;D. Planchard

  (2021)
  182 Citations

• Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis

  (2022)
  173 Citations

• Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts.

  S. Stacchiotti;A.B. Miah;A.M. Frezza;C. Messiou

  (2021)
  173 Citations

• ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer.

  Evandro de Azambuja;Dario Trapani;Sibylle Loibl;Suzette Delaloge

  (2020)
  172 Citations

• Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial.

  Andrea Sartore-Bianchi;Sara Lonardi;Cosimo Martino;Elisabetta Fenocchio

  (2020)
  139 Citations

• ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer.

  Antonio Passaro;Alfredo Addeo;Christophe Von Garnier;Fiona Blackhall

  (2020)
  131 Citations

• ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer

  (2020)
  128 Citations